Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracellular signaling

PPAR Research

Volumn , Issue , 2008, Pages

  Giulia, Cantini ^a   Adriana, Lombardi ^a   Elisabetta, Piscitelli ^a   Poli, Giada ^a   Elisabetta, Ceni ^a   Sara, Marchiani ^a   Tonino, Ercolino ^a   Andrea, Galli ^a   Mario, Serio ^a   Massimo, Mannelli ^a   Michaela, Luconi ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ROSIGLITAZONE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADRENAL CORTEX CARCINOMA; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 49749113948     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/904041     Document Type: Article

References (24)

1. Lipsett M. B., Hertz R., Ross G. T., Clinical and pathophysiologic aspects of adrenocortical carcinoma The American Journal of Medicine 1963 35 3 374 383
2. Allolio B., Fassnacht M., Adrenocortical carcinoma: clinical update The Journal of Clinical Endocrinology & Metabolism 2006 91 6 2027 2037
3. Kirschner L. S., Emerging treatment strategies for adrenocortical carcinoma: a new hope The Journal of Clinical Endocrinology & Metabolism 2006 91 1 14 21
4. Bertherat J., Groussin L., Bertagna X., Mechanisms of disease: adrenocortical tumors-molecular advances and clinical perspectives Nature Clinical Practice Endocrinology & Metabolism 2006 2 11 632 641
5. Khandwala H. M., McCutcheon I. E., Flyvbjerg A., Friend K. E., The effects of insulin-like growth factors on tumorigenesis and neoplastic growth Endocrine Reviews 2000 21 3 215 244
6. Boulle N., Logié A., Gicquel C., Perin L., Le Bouc Y., Increased levels of insulin-like growth factor II (IGF-II) and IGF- binding protein-2 are associated with malignancy in sporadic adrenocortical tumors The Journal of Clinical Endocrinology & Metabolism 1998 83 5 1713 1720
7. Weber M. M., Auernhammer C. J., Kiess W., Engelhardt D., Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands European Journal of Endocrinology 1997 136 3 296 303
8. Logié A., Boulle N., Gaston V., Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line Journal of Molecular Endocrinology 1999 23 1 23 32
9. Slater E. P., Diehl S. M., Langer P., Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors European Journal of Endocrinology 2006 154 4 587 598
10. Betz M. J., Shapiro I., Fassnacht M., Hahner S., Reincke M., Beuschlein F., Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation The Journal of Clinical Endocrinology & Metabolism 2005 90 7 3886 3896
11. Giannini S., Serio M., Galli A., Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity Journal of Endocrinological Investigation 2004 27 10 982 991
12. Gervois P., Fruchart J.-C., Staels B., Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors Nature Clinical Practice Endocrinology & Metabolism 2007 3 2 145 156
13. Galli A., Mello T., Ceni E., Surrenti E., Surrenti C., The potential of antidiabetic thiazolidinediones for anticancer therapy Expert Opinion on Investigational Drugs 2006 15 9 1039 1049
14. Lombardi A., Cantini G., Piscitelli E., A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-α and interferon-γ inflammatory effects in human endothelial cells Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 4 718 724
15. Panigrahy D., Huang S., Kieran M. W., Kaipainen A., PPARγ as a therapeutic target for tumor angiogenesis and metastasis Cancer Biology and Therapy 2005 4 7 687 693
16. Ferruzzi P., Ceni E., Tarocchi M., Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R The Journal of Clinical Endocrinology & Metabolism 2005 90 3 1332 1339
17. DeLean A., Munson P. J., Rodbard D., Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves American Journal of Physiology 1978 235 2 E97 102
18. Doepfner K. T., Spertini O., Arcaro A., Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway Leukemia 2007 21 9 1921 1930
19. Nolan J. J., Jones N. P., Patwardhan R., Deacon L. F., Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus Diabetic Medicine 2000 17 4 287 294
20. Kempná P., Hofer G., Mullis P. E., Flück C. E., Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2 Molecular Pharmacology 2007 71 3 787 798
21. D'Ercole A. J., Insulin-like growth factors and their receptors in growth Endocrinology and Metabolism Clinics of North America 1996 25 3 573 590
22. Lecka-Czernik B., Ackert-Bicknell C., Adamo M. L., Activation of peroxisome proliferator-activated receptorγ (PPARγ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo Endocrinology 2007 148 2 903 911
23. He G., Sung Y. M., DiGiovanni J., Fischer S. M., Thiazolidinediones inhibit insulin-like growth factor-I-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity Cancer Research 2006 66 3 1873 1879
24. Chapelsky M. C., Thompson-Culkin K., Miller A. K., Sack M., Blum R., Freed M. I., Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency Journal of Clinical Pharmacology 2003 43 3 252 259